A comprehensive understanding of this pathway may facilitate research aimed at identifying potential therapeutic targets to modulate the aberrant TNFR2/HIF-1α activity, which is crucial for the treatment of cancers including BC. This evidence concerns the gene HIF1A and breast cancer.